Alkmaar

• A randomized phase II study comparing atezolizumab after concurrent chemoradiotherapy with chemoradiotherapy alone in limited disease small- … Ended recruitment
  2024-515755-37-00 4 2018-07-31 Limited disease small-cell lung cancer
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended recruitment
  2024-516204-42-00 5 2017-11-21 Breast cancer
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended recruitment
  2023-510298-33-00 4 2016-11-29 Prostate Cancer
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not res … Ended recruitment
  2023-509221-47-00 5 2014-02-12 Castration-Resistant Prostate Cancer
• Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumaB as first-lin … Ended recruitment
  2024-516202-39-00 4 2013-10-10 Metastatic breast cancer
• WOMEN&More: Efficacy, safety, and acceptability of mifepristone 50 mg once-weekly as a contraceptive Ended
  2022-502694-41-00 5 2025-04-14 Contraception
• A trial to learn how safe AZD8630 is and how well it works in adults with uncontrolled asthma. Ended
  2024-514228-18-00 4 2025-01-16 Asthma in adults who remain uncontrolled despite medium to high dose I
• THE (COST)EFFECTIVENESS OF NEOADJUVANT FOLFIRINOX VERSUS NEOADJUVANT GEMCITABINE BASED CHEMORADIOTHERAPY AND ADJUVANT GEMCITABINE FOR (BORDE … Ended
  2024-516260-29-00 5 2024-10-10 non-metastatic (borderline) resectable pancreatic cancer
• A Proof-of-Concept study to assess the efficacy, safety and tolerability of itepekimab (anti-IL-33 mAb) in participants with non-cystic fibr … Ended
  2023-508663-70-00 4 2024-06-18 Bronchiectasis
• A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended
  2022-501418-69-00 5 2023-11-21 Acute Coronary Syndrome
• A Phase 3, 52-Week, Randomized, Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory or Une … Ended
  2024-513460-26-00 5 2023-03-29 Refractory Chronic Cough, Including Unexplained Chronic Cough
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Ended
  2023-503673-38-00 5 2019-05-24 Adults at high risk of cardiovascular events without prior MI or strok
• A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who … Ended
  2023-510557-42-00 4 2017-07-10 chronic lymphocytic leukemia
• GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended
  2024-511048-22-00 4 2016-10-27 Chronic lymphocytic leukemia
• Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN) Ended
  2024-516581-11-00 5 Advanced stage NSCLC

Showing 73–91 of 91 trials